<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905174</url>
  </required_header>
  <id_info>
    <org_study_id>2017/MING</org_study_id>
    <nct_id>NCT03905174</nct_id>
  </id_info>
  <brief_title>Massive Implants the Next Generation</brief_title>
  <acronym>MING</acronym>
  <official_title>A Randomised, Single Blind Study Assessing Radiological Outcomes for Massive Segmental Femoral Replacements Using Either Porous Collar or Porous Collar With HA or Porous Collar With HA and Autologous Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iva Hauptmannova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adler Ortho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal National Orthopaedic Hospital NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will review the use of massive segmental replacements in the femur, which have a
      porous collar with and without HA, and autologous stem cell augment. This is a randomised
      controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current surgical treatment of bone cancer patients and revision limb salvage requires
      usage of massive endoprosthetic bone implants. The incidence of aseptic loosening is a major
      cause of prosthesis failure in these patients, exploring ways to reduce such failures would
      allow extending longevity of massive implants in a relatively young population.

      Current published literature stipulates that osteointegration could improve longevity of
      massive implants. Evidence suggests that usage of osteointegrated hydroxyapatite (HA) coated
      collar would reduce the incidence of aseptic loosening around the cemented intramedullary
      stem in distal femoral bone prosthesis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiological outcomes (X-ray, CT)</measure>
    <time_frame>at 26 weeks (+/- 2 weeks)</time_frame>
    <description>radiological outcomes to determine integration of implant into bone - bone growth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological outcomes (X-ray, CT)</measure>
    <time_frame>at 1 year (+/- 2 weeks)</time_frame>
    <description>radiological outcomes to determine integration of implant into bone - bone growth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological outcomes (X-ray, CT)</measure>
    <time_frame>at 2 years (+/- 2 weeks)</time_frame>
    <description>radiological outcomes to determine integration of implant into bone - bone growth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Score (VAS) pain score</measure>
    <time_frame>up to 2 years (+/- 2 weeks)</time_frame>
    <description>visual analogue pain score to determine improvement of pain over time, 0 to 10 scale will be used (0 = no pain, higher the number the worse the pain)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bone Cancer</condition>
  <condition>Bone Diseases</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A porous collar for either distal or proximal femoral replacements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment + HA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A porous collar with hydroxyapatite (HA) for either distal or proximal femoral replacements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment + HA + autogenic cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A porous collar with hydroxyapatite (HA) and stem cells for either distal or proximal femoral replacements</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>custom made device</intervention_name>
    <description>surgical intervention to place custom made orthopaedic device</description>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_label>standard treatment + HA</arm_group_label>
    <arm_group_label>standard treatment + HA + autogenic cells</arm_group_label>
    <other_name>custom orthopaedic implantable device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bone cancer patients requiring primary or revision femoral segmental replacements and
             non-cancer patients requiring revision femoral segment replacement for aseptic
             loosening

          -  Male or female, aged 18 years or above

          -  Able to provide consent

        Exclusion Criteria:

          -  unable/unwilling to consent

          -  revisions surgery due to infection

          -  bone cancer patients excluded from stem cell arm

          -  bone cancer patients with pathological fractures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panos Gikas, PhD FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal National Orthopaedic Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Panos Gikas, PhD FRCS</last_name>
    <phone>02089092300</phone>
    <email>rnoh.research@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esther Hanison, BSc</last_name>
    <phone>02089092300</phone>
    <email>rnoh.research@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal National Orthopaedic Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <state>Middx</state>
        <zip>HA7 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Hanison, BSc</last_name>
      <phone>2089542300</phone>
      <email>rnoh.research@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Panos Gikas, PhD FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Royal National Orthopaedic Hospital NHS Trust</investigator_affiliation>
    <investigator_full_name>Iva Hauptmannova</investigator_full_name>
    <investigator_title>Head of Research &amp; Innovation</investigator_title>
  </responsible_party>
  <keyword>revision surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

